NeuroOne Insider Sells Small Stake as Q1 Results and Coverage Lift Focus on NMTC
NeuroOne Medical Technologies Business Development Director Mark Christianson sold 15,363 shares on March 30, 2026 and another 253 shares on March 31, 2026. The transactions, disclosed in a Form 4 filed April 1, 2026, followed the company’s Q1 Fiscal 2026 results and came as the stock traded around $0.80. Analysts maintain price targets from $1.50 …